Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.
Authors
Jagpreet Chhatwal
Harvard Medical School, Boston, MA
Jagpreet Chhatwal , Sumeyye Samur , Ju Dong Yang , Lewis R. Roberts , Mindie Nguyen , A. Burak Ozbay , Turgay Ayer , Neehar Parikh , Amit G. Singal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Prevention, Screening, and Hereditary Cancers
DOI
10.1200/JCO.2022.40.4_suppl.405
Abstract #
405
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.
First Author: Naga P. Chalasani
Poster
2023 ASCO Annual Meeting
Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.
First Author: Rui Liu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Plasma hPG80 (circulating progastrin) as a novel prognostic biomarker for hepatocellular carcinoma at early to intermediate stages (BCLC 0 to B).
First Author: Alexandre Prieur
Poster
2021 ASCO Annual Meeting
Prognostic value of plasma hPG80 (circulating progastrin), alone or in combination with Alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma.
First Author: Alexandre Prieur